21 results about "MMP1" patented technology

The invention relates to the technical field of cosmetics, and discloses a cosmetic composition, a preparation method and application of the cosmetic composition in anti-aging and anti-wrinkle skin. The preparation method comprises the following steps: expressing SKAP2 protein through prokaryote escherichia coli, extracting milk exosome, wrapping the SKAP2 protein into the milk exosome, and mixing the milk exosome containing the SKAP2 protein with trehalose dihydrate, water and CMC (Carboxymethyl Cellulose) to prepare a hydrogel preparation which can be used as a cosmetic composition applied to gel coating agents, masks, toner and dry powder patches. The anti-wrinkle effect is achieved by inhibiting the activity of matrix metalloproteinase 1 (MMP1).

The invention belongs to the technical field of protein, and relates to a peptide for preventing collagen loss and a preparation method thereof. The amino acid sequence of the peptide is KSYELPDGQVITIG, and the key active fragment of the peptide is ELPDGQVIT. The peptide is obtained by performing enzymolysis on degreased maggot powder with alkaline protease, trypsin, papain, neutral protease and flavourzyme. The peptide can inhibit the expression of MMP1 and MMP9 in L929 cells after UVA irradiation, and alleviate the loss of collagen.

The invention belongs to the technical field of microorganisms, and finds that trans-cinnamic acid is a key metabolite of microorganism staphylococcus epidermidis H62-3 for the first time, so that a new method is provided for preparation of the trans-cinnamic acid, and meanwhile, the problem of environmental pollution caused by chemical synthesis of the trans-cinnamic acid is also avoided. In addition, the invention also relates to an application of trans-cinnamic acid in preparation of a product for resisting skin photoaging. The trans-cinnamic acid provided by the invention has the effect of resisting skin photoaging, can effectively relieve the transcriptional level of senescence-related genes p53, p21 and p16 and inflammatory factors IL-1beta, IL-6 and TNF-alpha induced by UVB irradiation, reduces the level of reactive oxygen species (ROS), inhibits the expression of matrix metalloproteinases MMP9, MMP3 and MMP1, promotes the synthesis of I-type collagen (COL1), and can be used for preparing anti-aging drugs for treating skin aging. And the activity of beta-galactosidase (SA-beta-gal) related to aging is reduced.

This invention belongs to the field of biomedical technology, specifically relating to a GDF15 antagonistic peptide and its application. The amino acid sequence of the antagonistic peptide is shown in SEQ ID NO.1. To improve drug stability and blood-brain barrier penetration, GDF15-A-Pep was fused with albumin and transferrin receptor nanobodies. Biological validation results showed that the fusion protein significantly inhibited GDF15-induced MMP1 transcription and protein expression, and exhibited potent antagonistic activity in reporter gene experiments. This invention not only reveals the key structural basis of GDF15 receptor recognition but also provides experimental evidence for the development of novel GDF15 antagonistic drugs with central regulatory potential.

The invention discloses application of vicenin-2 in preparation of a pharmaceutical preparation for treating and / or preventing rosacea, and belongs to the technical field of biological medicines. Vitin-2 blocks conduction of an IL-17 signal channel through targeted regulation and control of an IL-17RA / ACT1 / TRAF6 axis, further inhibits activation of an NF-kappa B signal channel, reduces levels of inflammatory factors TNF alpha, IL-6, IL-1beta and IL-8 induced by LL-37, inhibits expression of mRNA of TNF alpha, IL-6 and IL-1beta, inhibits phosphorylation of key protein of the channel, reduces protein expression levels of MMP1 and MMP3 at the downstream of the channel, and further inhibits activation of an NF-kappa B signal channel. Further, the effect of resisting the acne rosacea inflammatory response is achieved. Besides, the external vicenin-2 solution can relieve back erythema and angiotelectasis of a rosacea-like mouse model, pathological tissue section HE staining shows that the external vicenin-2 solution can relieve LL-37-induced skin inflammation infiltration, and the weight of a mouse is not obviously reduced compared with that before treatment; and the skin erythema and scales of mice are not generated by external use of the vicainin-2 solution.

The present invention relates to a composition which is for preventing or treating bone diseases and includes CCR2 as an active ingredient. It was confirmed that a C—C chemokine receptor type 2 (CCR2) protein, a polynucleotide encoding the CCR2 protein, or a mesenchymal stem cell transduced with the CCR2 according to the present invention neutralize bone disease factor MCP-1, thereby reducing the collagen epitope (CTX-II) and collagen metabolism factors (MMP1 and MMP3) relating to collagen absorption in the body. In addition, it was confirmed that the expression of the SOX9 gene and anti-inflammatory cytokines (TGF-β and IL-10) related to cartilage differentiation was significantly increased. Thus, the present invention has excellent regenerative ability against osteoarthritis and excellent pain suppression and alleviation effects, and thus can be effectively used for preventing or treating bone diseases such as osteoarthritis.

The invention relates to a tuberculosis antigen specific host biomarker for detecting tuberculosis infection and a kit, and belongs to the field of biological medicines. The biomarker comprises IFN gamma, CXCL10, IL-2, IL-3, GBP6, ULBP2, CXCL11, ATP13A3, RHOV, ATP2B1, IL-22 and MMP1 (Metallocin Protein Protein 1). According to the present invention, the specific RD1 region antigen or peptide pool from mycobacterium tuberculosis and the specific RD2 region antigen or peptide pool from mycobacterium tuberculosis are jointly used as the antigen irritants to stimulate peripheral whole blood or peripheral blood mononuclear cells (PBMCs) of an individual to be detected, and then the expression quantity change of the host biomarker before and after the stimulation is detected; the kit can effectively distinguish tuberculosis infected patients from non-tuberculosis infected individuals, can identify and diagnose active tuberculosis and latent tuberculosis infected patients, solves the defects of insufficient sensitivity and limited specificity of the existing diagnostic technology, and has high diagnostic efficiency.

The invention relates to the technical field of prediction models, and particularly discloses a gout recurrence prediction model and a construction method thereof. Clinical index data and the standardized protein expression level of immune-related molecules in plasma are used for constructing the gout recurrence prediction model, the gout recurrence prediction model obtained through the method has the stable prediction capacity, and MMP1 achieves the very high AUC value and accuracy and the lowest Brier score.

The application discloses application of extracellular vesicles from Eclipta prostrata L. The extracellular vesicles are extracted from Eclipta prostrata L. by using ultracentrifugation and ultrafiltration, and the extracted vesicles are complete in appearance and good in dispersibility, and have the characteristics of high yield, fast separation, low cost and easy scaling. The extracted vesicles can be successfully taken by animal cells. After being taken, the vesicles play the roles of antioxidation and anti-aging, can significantly reduce ultraviolet-induced matrix metalloproteinase 1 (MMP1) expression, promote collagen I (COL-I) generation, improve ultraviolet-induced skin photoaging, and the effect is stronger than that of Eclipta prostrata L. alcohol extract, so that the extracellular vesicles from Eclipta prostrata L. provide a new strategy for skin aging and anti-aging treatment.

To enable rapid and accurate diagnosis of oral lichen planus on the basis of a noninvasive and easily accessible sample such as saliva.SOLUTION: The present invention relates to a biomarker composition for diagnosing oral lichen planus, which is selected from the group consisting of CLC, TNFAIP8, EVI5L, ISG15, PIGS, SLC4A1, MYH1, CLTA, CCAR2, GRK6, ATP5F1D, ASRGL1, BST1, CYBA, ASAP1, MAP2K4, RNASE2, NIPSNAP2, MMP1, EWSR1, CCL28, LEG1, ACBP, APOM, TFF3, FOLR1, WFDC2, SERPINA1, SLURP1, DEFB4A, SLPI, IGFBP7, IGLV1-51, SERPINI1, IGLV3-9, SERPINA3, SPATS2L, APOC1, IGKV2-29, and KALRN.SELECTED DRAWING: Figure 1

This invention belongs to the field of protein technology and relates to a peptide that prevents collagen loss and its preparation method. The amino acid sequence of the peptide is KSYELPDGQVITIG, with the key active fragment being ELPDGQVIT. The peptide is obtained by enzymatic hydrolysis of defatted grain insect powder using alkaline protease, trypsin, papain, neutral protease, and flavor protease. This peptide can inhibit the expression of MMP1 and MMP9 in L929 cells after UVA irradiation, thus alleviating collagen loss.

The invention belongs to the field of daily chemicals, and provides an anti-wrinkle and firming composition and application, and the anti-aging and anti-inflammatory composition provided by the invention comprises tripeptide, chlamydomonas and a grape flower cell extract. According to the composition provided by the invention, the tripeptide, the chlamydomonas and the grape flower cell extract are compounded for use, all the components are mutually matched and promoted, and a synergistic effect is achieved in the aspects of promoting Collagen I up-regulation expression and inhibiting MMP1 expression, so that the composition has anti-wrinkle and firming effects. In addition, the composition provided by the invention can also significantly reduce inflammatory factors, such as IL-8 expression, and has an anti-inflammatory effect.

The invention discloses a preparation method and application of recombinant type VI collagen, amino acids from the 1489th site to the 1518th site of a human type VI collagen alpha5 chain are adopted as target proteins, after codon optimization, the target proteins are transformed to E.coli BL 21, expression of the target proteins is detected, high-yield strains are screened, and the recombinant type VI collagen is obtained. Systematically optimizing expression conditions such as a culture medium, an inducer, culture temperature, culture time and the like to obtain an engineering strain with stable expression; the recombinant collagen is purified through affinity chromatography, and the recombinant collagen which has antioxidant activity, has protection and repair effects on ultraviolet-induced skin cell photoaging and has influence effects on skin cell proliferation, adhesion and migration is obtained. The recombinant collagen can obviously reduce the mRNA expression quantity of inflammatory factors IL-1beta, IL-8 and TNF-alpha and matrix metalloproteinase MMP1, so that the degree of inflammatory reaction in photoaging HaCaT cells is reduced, and a theoretical basis is provided for application of the recombinant collagen in the fields of food nutrition, health care and beauty treatment, clinical treatment, medical beauty treatment and the like.

The application discloses application of isoprenyl cysteine carboxymethyltransferase as a rheumatoid arthritis treatment target in preparation of a rheumatoid arthritis treatment drug. The application finds that the expression of ICMT is down-regulated after NSUN2 is knocked out, further research on the expression level of ICMT in RA FLS finds that the mRNA and protein expression of RA FLS ICMT is obviously up-regulated, the cell migration and invasion ability is reduced after ICMT is knocked down, and the expression of MMPs such as MMP1, MMP3 and MMP9 of RA FLS is obviously inhibited. The above results show that ICMT can regulate the abnormal migration and invasion of RA FLS, and targeting ICMT can become a new means to prevent RA joint destruction. Therefore, the application provides an effective treatment target for RA, and provides a new idea for clinical treatment of RA.

Compositions may include the cosmetic use of an active agent for the treatment and / or prevention of skin aging, wherein the agent is capable of inhibiting aging-related secretion phenotypes by i) reducing the release of IL-6, IL-8, TNF-alpha, and matrix metallopeptidase-1 (MMP1); ii) reducing the activity of b-galactosidase, iii) reducing the biosynthesis of secretory crimp-associated protein 4 (SFRP 4), and iv) reducing the expression of p21 in fibroblasts.

This application discloses a combination of gene markers for predicting ovarian cancer prognosis, immunotherapy response, or immunophenotype, and their applications, belonging to the field of molecular diagnostic technology for ovarian cancer. The combination of gene markers includes... MMP1 , GJB2 , PLPP4 , MME , GREM1 , COL10A1 , CTHRC1 , CEMIP , MMP11 and NTM The combination of gene markers presented in this application can not only predict the prognostic risk of ovarian cancer, but also predict the immunotherapy response and immunophenotype of ovarian cancer samples, with excellent performance.

The disclosure provides a method for treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof, wherein the subject is identified as having a low stromal gene signature score. In some aspects, the low stromal gene signature score is determined by measuring the expression of a panel of stromal genes in a tumor sample obtained from the subject, wherein the stromal gene panel comprises at least four genes selected from CDH1, CDH2, MMP1, MMP2, ITGA1, ITGA2, ITGA3, ITGA5, ITGA7, ITGA11, TGFB1, and TGFB1; at least four genes selected from TGFB1, TGFBR2, ACTA2, COL4A1, TAGLN, SH3PXD2A, TWIST1, ZEB1, and ZEB2; or MMP2 and MMP9.

The invention relates to the field of biological medicine, and discloses a biomarker for detecting a PARP1 function and application of the biomarker, and the biomarker comprises CBX5, CKAP2, NKTR, PTCH1, ZNF318, CENPF, ARID4B, CDK19, SRCAP, CELF2, CBFA2T3, TIAM1, SARDH, IDI1, BIRC6, PAN3, PRSS23, ITGA2, PROCR, S100A2, GRN, IFIT1, MMP1, RBPMS, JAG1, IFI27, OASL, HMGA2, SPHK1, KLF10, MYO10, ARRDC4, PLAUR, IER3, PTGS2, ANKRD29 and The biomarker is a regulatory gene of the PARP1, and has higher specificity than that of the PARP1.

This application belongs to the field of daily chemical products and provides an anti-wrinkle and firming composition and its application. The anti-aging and anti-inflammatory composition provided by this application includes a tripeptide, snow algae, and grape flower cell extract. The composition provided by this application combines the tripeptide, snow algae, and grape flower cell extract, with each component working synergistically and promoting each other. It achieves a synergistic effect in promoting the upregulation of Collagen I expression and inhibiting MMP1 expression, thereby exhibiting an anti-wrinkle and firming effect. In addition, the composition provided by this application can also significantly reduce the expression of inflammatory factors, such as IL-8, thus possessing an anti-inflammatory effect.

Inventors tested keratinocytes isolated from a patient with severe LM332-associated JEB carrying a homozygous variant (c.183delCA) in the LAMB3 gene (Vailly et al., 1998). Pathogenic variants in the LAMB3 gene account for 80% of severe LM332-associated JEB (Lincoln et al., 2018). They confirmed altered cell adhesion in these keratinocytes but then 10 found that treatment with PRIMA-1MET rescued cell adhesion in a dose-dependent manner. To further validate the rescuing effect of PRIMA-1MET, two additional epidermal cell lines derived from two patients with JEB carrying pathogenic variants in the ITGB4 gene were tested under the same conditions. These two JEB cells displayed similar altered cell adhesion, which is also partially 15 rescued by PRIMA-1MET.Asfor the LAMB3-associated JEB cells, PRIMA-1MET treatment increased matrix metal-loproteinase 1 gene MMP1 and ADAM8 gene expression in these cells (Figure 2b). Altogether, our results validate the effect of PRIMA-1MET on three different JEB lines, suggesting that it could benefit patients with JEB.

The present invention relates to an anti-fibrotic composition for preventing or treating fatty liver or liver cirrhosis, the composition containing jujube polysaccharides as an active ingredient. The jujube polysaccharide-containing composition according to the present invention can significantly inhibit the expression of fibrosis-related mRNAs (Tgf-β, Col1a1, Col4a1, Pdgfb, Mmp1, Mmp2, and Timp1) induced in LX2 hepatic stellate cells by TGF-β1, and the whole-cell expression and nucleus expression of fibrosis-related proteins (p-SMAD2, SMAD2, p-SMAD3, SMAD3, and SMAD4). In addition, the jujube polysaccharide-containing composition can significantly suppress body fat mass (fat mass (g), adiposity (% fat)) increased by a high-fat, high-fructose diet (HFHFD), and significantly reduce hepatic steatosis and inflammation. Therefore, the jujube polysaccharide-containing composition according to the present invention is expected to be advantageously used as an anti-fibrotic composition for preventing, alleviating, and treating fatty liver or liver cirrhosis.